Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Clinical_Trials
|
| gptkbp:aims_to |
reduce LDL cholesterol
|
| gptkbp:business_model |
institutional review board
|
| gptkbp:completed |
gptkb:2018
|
| gptkbp:conducted |
multiple countries
|
| gptkbp:evaluates |
effect of alirocumab
|
| gptkbp:focuses_on |
cardiovascular outcomes
|
| gptkbp:funding |
gptkb:pharmaceuticals
|
| gptkbp:has_data_analysis_method |
statistical analysis
multivariate analysis |
| gptkbp:has_lead_investigator |
gptkb:Dr._Steven_Nissen
|
| gptkbp:has_limitations |
generalizability of results
short follow-up period specific patient population potential for bias |
| gptkbp:has_primary_outcome |
time to first occurrence of major adverse cardiovascular events
|
| gptkbp:has_research_focus |
alirocumab significantly reduces cardiovascular events
|
| gptkbp:has_secondary_outcome |
quality of life assessments
changes in LDL cholesterol levels changes in apolipoprotein B levels changes in non-HDL cholesterol levels changes in triglyceride levels |
| https://www.w3.org/2000/01/rdf-schema#label |
ODYSSEY Outcomes Trial
|
| gptkbp:involves |
patients with atherosclerotic cardiovascular disease
patients with high cholesterol |
| gptkbp:is_cited_in |
numerous subsequent studies
|
| gptkbp:is_compared_to |
alirocumab vs placebo
|
| gptkbp:is_controlled |
placebo-controlled study
|
| gptkbp:is_discussed_in |
medical conferences
|
| gptkbp:is_influential_in |
guidelines for cholesterol treatment
|
| gptkbp:is_multicenter |
gptkb:test_subjects
|
| gptkbp:is_part_of |
ODYSSEY program
clinical research on PCSK9 inhibitors |
| gptkbp:is_randomized |
double-blind study
|
| gptkbp:is_relevant_to |
cardiovascular health
cholesterol management |
| gptkbp:measures |
major adverse cardiovascular events
|
| gptkbp:participants |
over 18,000 patients
|
| gptkbp:provides_information_on |
clinical assessments
laboratory tests patient questionnaires |
| gptkbp:publication_year |
gptkb:2019
|
| gptkbp:published_in |
gptkb:The_New_England_Journal_of_Medicine
|
| gptkbp:registration |
gptkb:Clinical_Trials.gov
|
| gptkbp:results_indicate |
reduction in heart attack risk
reduction in cardiovascular death risk reduction in stroke risk |
| gptkbp:sponsored_by |
gptkb:Sanofi
|
| gptkbp:started_in |
gptkb:2015
|
| gptkbp:uses_drug |
gptkb:alirocumab
|